NCT07599982招募中不适用
Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes
DreaMed Diabetes6 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2026年5月25日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 102
- 试验地点
- 6
- 主要终点
- CGM-measured percent time <54mg/dL
研究概览
简要总结
A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis, based on investigator assessment, of T1D or T2D of at least 6 months duration at time of informed consent
- •Insulin therapy as follows:
- •If T1D, using MDI insulin therapy for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either (a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) meal-size-based dosing (small, normal, large); and taking
- •1 basal insulin injection per day for at least 1 week prior to screening
- •If T2D, either:
- •i. not using insulin in the 3 months prior to screening, but require initiation of a basal-only insulin regimen based on investigator assessment ii. using only basal insulin for at least 3 months prior to screening and taking 1 basal insulin injection per day for at least 1 week prior to screening iii. using MDI for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either
- •(a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) mealsize-based dosing (small, normal, large); and taking 1 basal insulin injection per day for at least 1 week prior to screening
- •Age at time of consent 18-80 years
- •HbA1c >7.5% and <12% as measured by point-of-care device or local lab at the time of screening
- •Using only injected insulin types that are specified in the MODI Instructions for Use materials
- •Stable doses of non-insulin glucose lowering medications over the 4 weeks preceding screening as determined by Investigator and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons
- •Stable doses of weight loss medications that may have a meaningful effect on glycemic control over the 4 weeks preceding screening and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons
- •Weight between 80 - 440 lb at the time of screening
- •Willing to use FSL 3 System according to manufacturer instructions and to avoid use of any other personal CGM system during the period of study participation
- •Willing to document insulin delivery, meals, and daily activities in the Diary mobile app
- •Has a smartphone compatible with study requirements: either iOS version 17.0 or higher, or Android version 10.0 or higher, and willing to install required apps and use them as instructed during the period of study participation, with internet connectivity for a data upload at least once per day.
- •Is deemed an appropriate candidate for automatic insulin guidance therapy per Investigator assessment
- •Investigator has confidence that the participant has the cognitive ability necessary for study participation, can successfully operate all study devices, and can adhere to the protocol
- •Has a sufficient understanding of written/spoken English for legally effective informed consent and successful use of the study mobile apps
- •If woman of childbearing potential, is willing and able to have pregnancy testing
排除标准
- •Use of an insulin pump within 3 months prior to informed consent
- •Use of mixed insulin or intermediate insulin (NPH) within the past 3 months prior to screening
- •Taking more than 128 units of daily basal insulin or more than 79 units in a single bolus insulin injection in the 7 days prior to screening
- •Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
- •Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
- •Any planned surgery during the study which could be considered major in the judgment of the investigator
- •History of more than 1 severe hypoglycemic event in the 6 months prior to screening
- •History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening
- •Blood disorder or dyscrasia within 3 months prior to screening which in the investigator's opinion could interfere with determination of HbA1c
- •Any condition or intervention that may affect red blood cell turnover, in the 3 months prior to the study and during the study, such as blood transfusion or donation
- •Has taken oral or injectable corticosteroids within 2 weeks prior to screening or plans to take oral or injectable corticosteroids during the study
- •Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
- •Is an employee of DreaMed Diabetes, is a study Investigator or a member of the Investigator's study team, or is immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
- •Participation in another clinical study using an investigational drug or device in the 90 days prior to screening or intends to participate during the study period
- •Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months postmenopausal)
- •Unable to tolerate adhesive tape or has any unresolved skin condition that could impact the CGM sensor
研究组 & 干预措施
MODI dose guidance, insulin titration application
Experimental
干预措施: MODI Algorithm (Device)
结局指标
主要结局
CGM-measured percent time <54mg/dL
时间窗: 13 weeks
Change in CGM-measured percent time \<54 mg/dL from 2 weeks of baseline to 4 weeks prior to the dose guidance week 12 visit (non-inferiority with margin 0.5%)
次要结局
- HbA1c(13 weeks)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
To Evaluate the Efficacy and Safety of the Insulin Patch Pump System in Patients With Diabetes.Type 2 DiabetesType 1 DiabetesNCT07403565Suzhou Hechun Medical Technology Co., Ltd.161
已完成
不适用
Efficacy and Safety of an Intelligent Insulin-Dosing Decision Support System for Glycemic Control in Patients With Type 2 Diabetes: A Randomized Controlled StudyNCT07291804Third Affiliated Hospital, Sun Yat-Sen University140
招募中
1 期
评价 E10I 治疗 2 型糖尿病的安全性、耐受性以及初步有效性的 I 期临床研究2 型糖尿病CTR20252968广州达博生物制品有限公司 / 创智行（广州）生物科技有限公司
尚未招募
Unknown
Moisturizing activity of Hydration SerumCTRI/2026/01/100030Anju LLC10
尚未招募
不适用
A Study to Assess the Safety and Effectiveness of the Smart Insulin Recommendation App (SIRA) in Managing Blood Sugar Levels in Heart Surgery Patients with DiabetesType 2 diabetes mellitus with unspecified complications, (2) ICD-10 Condition: E116||Type 2 diabetes mellitus with other specified complications, (3) ICD-10 Condition: E138||Other specified diabetes mellituswith unspecified complications, (4) ICD-10 Condition: Z488||Encounter for other specified postprocedural aftercare, (5) ICD-10 Condition: R739||Hyperglycemia, unspecified,CTRI/2025/07/090542CareOps Solutions Private Limited300